These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 25736863)

  • 21. Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer.
    Michieletto S; Saibene T; Evangelista L; Barbazza F; Grigoletto R; Rossi G; Ghiotto C; Bozza F
    Breast; 2014 Feb; 23(1):19-25. PubMed ID: 24189101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
    Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
    PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
    Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
    Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
    Bayraktar S; Amendola L; Gutierrez-Barrera AM; Hashmi SS; Amos C; Gambello M; Ready KJ; Arun B
    Breast; 2014 Dec; 23(6):770-4. PubMed ID: 25231195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
    Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
    Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
    Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
    Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
    Deb S; Jene N; ; Fox SB
    BMC Cancer; 2012 Nov; 12():510. PubMed ID: 23146383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P; Akram M; Benezra R; Brogi E
    Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and biological characteristics of breast cancer.
    Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
    J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.
    Loughrey M; Provan PJ; Byth K; ; Balleine RL
    Pathology; 2008 Jun; 40(4):352-8. PubMed ID: 18446624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
    Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
    Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
    Fostira F; Tsitlaidou M; Papadimitriou C; Pertesi M; Timotheadou E; Stavropoulou AV; Glentis S; Bournakis E; Bobos M; Pectasides D; Papakostas P; Pentheroudakis G; Gogas H; Skarlos P; Samantas E; Bafaloukos D; Kosmidis PA; Koutras A; Yannoukakos D; Konstantopoulou I; Fountzilas G
    Breast Cancer Res Treat; 2012 Jul; 134(1):353-62. PubMed ID: 22434525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The "portrait" of hereditary breast cancer.
    Lacroix M; Leclercq G
    Breast Cancer Res Treat; 2005 Feb; 89(3):297-304. PubMed ID: 15754129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.